The Cooper (MEX:COO) ROCE %: -1.03% (As of Apr. 2026)

What is The Cooper ROCE %?

The Cooper MEX:COO 89 ROCE % is -1.03% as of Apr. 2026. GuruFocus rates MEX:COO with a GF Score™ of 89/100 and a GF Value™ of MXN1,702.46 (Significantly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. The Cooper's annualized ROCE % for the quarter that ended in Apr. 2026 was -1.03%.

The Cooper (MEX:COO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

The Cooper ROCE % Related Terms

The Cooper ROCE % Historical Data

* Premium members only.

The historical data trend for The Cooper's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The Cooper ROCE % Chart

The Cooper Annual Data

Trend

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

Oct25

ROCE %

Get a 7-Day Free Trial

6.95

5.49

4.73

6.66

5.68

The Cooper Quarterly Data
	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25	Apr25	Jul25	Oct25	Jan26	Apr26
ROCE %	Get a 7-Day Free Trial															5.81	6.10	4.95	7.50	-1.03

89GF Score

The Cooper Companies Inc MEX:COO

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

The Cooper ROCE % Calculation

The Cooper's annualized ROCE % for the fiscal year that ended in Oct. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Oct. 2025 )		(A: Oct. 2024 )		(A: Oct. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Oct. 2025 )		(A: Oct. 2024 )		(A: Oct. 2025 )
	=	12361.242	/	( ( (246690.697 - 20488.116)	+	(229880.158 - 20638.545) )	/ 2 )
	=	12361.242	/	( (226202.581	+	209241.613)	/ 2 )
	=	12361.242	/	217722.097
	=	5.68 %

The Cooper's ROCE % of for the quarter that ended in Apr. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Apr. 2026 )		(Q: Jan. 2026 )		(Q: Apr. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Apr. 2026 )		(Q: Jan. 2026 )		(Q: Apr. 2026 )
	=	-1926.772	/	( ( (215551.173 - 27684.278)	+	(218641.215 - 31611.306) )	/ 2 )
	=	-1926.772	/	( ( 187866.895	+	187029.909 )	/ 2 )
	=	-1926.772	/	187448.402
	=	-1.03 %

(1) Note: The EBIT data used here is four times the quarterly (Apr. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -1.03% mean?

The Cooper (MEX:COO) has a ROCE % of -1.03% as of Apr. 2026.

Is The Cooper's ROCE % too high?

The Cooper's current ROCE % is -1.03%. Overall, The Cooper has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does The Cooper's ROCE % compare to ALGN and SOLV?

The Cooper's ROCE % of -1.03% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current ROCE % is -1.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is The Cooper stock overvalued right now?

Based on GuruFocus' analysis, The Cooper (MEX:COO) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,702.46, compared to a current price of MXN1,162.20 — trading 31.7% below its estimated fair value. The current ROCE % is -1.03%. The Cooper's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For The Cooper (MEX:COO), the current ROCE % is -1.03% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is The Cooper (MEX:COO) Overvalued in 2026?

Based on GuruFocus' analysis, The Cooper stock appears to be undervalued. The current stock price of MXN1,162.20 is trading 31.7% below its estimated GF Value™ of MXN1,702.46. GuruFocus considers The Cooper to be Significantly Undervalued.

Key valuation signals for MEX:COO:

ROCE %: -1.03%
GF Value™: MXN1,702.46 vs. price of MXN1,162.20 (31.7% below fair value)
GF Score™: 89/100 with 3 warning signs

No single metric tells the full story. See the MEX:COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

The Cooper Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies ALGN SOLV BAX ATR RGEN AVTR TFX STVN NVST MMSI ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST TSE:4543 XPAR:DIM

Other Exchanges COO:USA 1COO:Italy 0I3I:UK CP60:Germany C1OO34:Brazil

Address 6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, USA, 94583

Website https://www.coopercos.com

CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.

89GF Score

Get the complete analysis for MEX:COO

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,162.20

Price

MXN1,702.46

GF Value

View MEX:COO Analysis

See ROCE % data for all stocks →